¿ Biolex Inc., of Pittsboro, N.C., appointed Jan Turek as president and CEO. Turek most recently served as senior vice president and general manager for Bayer Corp.¿s biological products business unit in Raleigh, N.C. Biolex develops proteins derived from proprietary plant-based technology for the development of human and animal therapeutics and other biotechnology applications.
¿ Corixa Corp., of Seattle, and Nycomed Amersham Imaging, of Princeton, N.J., formed an agreement in which Corixa¿s U.S. sales force will co-promote Metastron, developed by Nycomed Amersham for the palliation of metastatic bone pain. Corixa will receive financial incentives based on specified sales levels. Corixa develops immunotherapeutics to treat and prevent autoimmune diseases.
¿ Immunex Corp., of Seattle, filed an investigational new drug application with the FDA to begin Phase I clinical studies with interleukin-1 receptor type II to assess tolerability. The studies will be initiated in patients with rheumatoid arthritis. Single and multiple dosing schedules will be evaluated, and the company expects to report results in mid-2002.
¿ Lexicon Genetics Inc., of The Woodlands, Texas, completed its merger with Coelacanth Corp., of Princeton, N.J. Coelacanth stockholders will receive an aggregate of 2,918,991 shares of Lexicon common stock. The exchange is based on the $10.9625 average closing price of Lexicon¿s stock for the 30 days ending three days prior to Thursday, the effective date of the merger. The deal is worth about $32 million. (See BioWorld Today, June 15, 2001.)
¿ Noonan/Russo Communications Inc., of New York, was acquired by Havas Advertising, of Paris, the world¿s fifth largest communications group. Noonan/Russo will operate as an independent unit within Havas¿ Diversified Agencies Group and will report to Patrick Lemarchand, chairman and CEO of Havas Advertising Diversified Agencies Group North America. Noonan/Russo was ranked as the 13th largest health care public relations firm in 2000, with revenues of $14 million. It has offices in New York, San Francisco and London and employs about 100 people. Noonan/Russo has been providing investor relations, public relations, and corporate and marketing communications since 1988. Financial terms were not disclosed.
¿ Oxford GlycoSciences plc, of Oxford, UK, initiated a clinical study in the U.S. with its Vevesca, for Type I Gaucher disease. The study is being conducted at New York University School of Medicine. The company announced on Thursday the acceptance of its marketing authorization application for Vevesca by the European Medicines Evaluation Agency.
¿ The Immune Reponse Corp., of Carlsbad, Calif., was the subject of a class action complaint by Weiss & Yourman on behalf of those who acquired Immune Response securities between May 17, 1999, and July 6, 2001. The complaint charges that Immune Response and Agouron Pharmaceuticals Inc., of La Jolla, Calif., withheld results of major clinical trial results of Remune, Immune¿s injectable HIV-1 immunogen-based HIV treatment. Agouron was, until July 6, Immune¿s partner in developing Remune. (See BioWorld Today, July 9, 2001.)